Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response published by Insight Pharma Reports in November, 2009. This report consists of 224 pages and the price starts from US $ 3195.

Introduction

Abstract

The human immune system can go awry, either attacking an individual' s body or producing an exag-gerated response to a foreign substance that is normally benign. In these situations, immunotherapies are needed to balance or suppress the unwarranted immune response.

In this report:

• Approximately 400 product candidates and development programs are identified.
• Current and emerging therapies for selected autoimmune or inflammatory disorders and prevention of organ transplant rejection, directed against a wide range of putative targets, are summarized.
• Specifically, more than 250 emerging autoimmune disease therapies, 80 asthma therapies in development, and 50+ therapy candidates for allergies are covered.
• The strategic consequences of intense competition in a crowded product space are considered.

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response reviews the problems of insuf-ficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system. This report identifies nearly 400 ongoing product candidates and development programs in these indication areas. The companies active in these areas range from multinational pharmaceutical companies with a number of active programs to small boutique start-ups working on a very defined topic.

Many of these programs involve “new” targets as well as a range of small-molecule and biological candidate therapeutics. The result is an extremely active, industry-wide product development race. As this report points out, this level of development activity for products addressing indications that frequently have quite limited patient populations is likely to lead to several rounds of ruthless attrition among these programs. Under such overheated conditions, the patient is likely to be less well served by innovation.

About the Author:

Lucy J. Sannes, PhD, MBA, is president of Sannes & Associates, a consulting firm specializing in evaluation and management of the biosciences. Before forming Sannes & Associates, she held management positions at Genetic Systems and Abbott Laboratories in product development, product support, and technical marketing. Dr. Sannes received her PhD in biological chemistry from the University of Michigan and her MBA from Seattle Pacific University.

Table of Contents

CHAPTER 1: INTRODUCTION

• 1.1. The Immune System
• 1.2. Scope of the Report

CHAPTER 2: REVIEW OF MAJOR DISEASES/ CONDITIONS TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM

• 2.1. Major Autoimmune Diseases
• Rheumatoid Arthritis
• Type 1 Diabetes Mellitus
• Inflammatory Bowel Disease- Crohn' s
  • Disease and Ulcerative Colitis
• Multiple Sclerosis
• Psoriasis
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• 2.2. Asthma
• 2.3. Allergies
• 2.4. Immune Suppression to Prevent Rejection of Organ Transplants

CHAPTER 3: CURRENT PHARMACOLOGICAL TREATMENT OPTIONS

• 3.1. Major Autoimmune Diseases
• Rheumatoid Arthritis
  • Nonsteroidal Anti-inflammatory Drugs
    • (NSAIDs)
  • Disease-Modifying Antirheumatic
    • Drugs (DMARDs)
  • Corticosteroids
  • Biological Response Modifiers
• Type 1 Diabetes Mellitus
• Inflammatory Bowel Disease- Crohn' s
  • Disease and Ulcerative Colitis
• Multiple Sclerosis
  • Interferon-beta
  • Copaxone (glatiramer acetate)
  • Novantrone (mitoxantrone)
  • Tysabri (natalizumab)
• Psoriasis
• Psoriatic Arthritis
• Systemic Lupus Erythematosus
• 3.2. Asthma
• 3.3. Allergies
• 3.4. Immune Suppression to Prevent Rejection of Organ Transplants

CHAPTER 4: CURRENT AND EMERGING APPROACHES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE

CHAPTER 5: EMERGING THERAPIES IN DEVELOPMENT FOR TREATMENT OF MAJOR AUTOIMMUNE DISEASES

• 5.1. Introduction
• 5.2. Abbott Laboratories
• 5.3. Biogen Idec
• 5.4. AstraZeneca
• 5.5. Bristol-Myers Squibb
• 5.6. Centocor Ortho Biotech
• 5.7. Centocor Ortho Biotech and Schering-Plough
• 5.8. Diamyd Medical
• 5.9. Eli Lilly and BioMS Medical
• 5.10. Eli Lilly and MacroGenics
• 5.11. Genzyme and Bayer
• 5.12. GlaxoSmithKline and Genmab
• 5.13. GlaxoSmithKline and Human Genome Sciences
• 5.14. GlaxoSmithKline and Tolerx
• 5.15. GlaxoSmithKline (Selected Additional Product Candidates and Research)
• 5.16. Isotechnika
• 5.17. Merck Serono and ZymoGenetics
• 5.18. Merck Serono
• 5.19. Novartis
• Multiple Sclerosis
• Rheumatoid Arthritis
• Psoriasis
• 5.20. Pfizer
• 5.21. Roche and Chugai Pharmaceutical
• 5.22. Roche and Genentech (A Wholly-Owned Member of the Roche Group)
• 5.23. Sanofi-Aventis
• 5.24. Takeda Pharmaceutical and Millennium Pharmaceuticals
• 5.25. Teva Pharmaceutical Industries and Active Biotech
• 5.26. UCB

CHAPTER 6: EMERGING THERAPIES FOR TREATMENT OF ASTHMA

• 6.1. Pipeline Overview
• 6.2. Abbott Laboratories and SkyePharma (Also Mundipharma and Kyorin)
• 6.3. Aerovance
• 6.4. Amgen
• 6.5. AstraZeneca
• 6.6. Ception Therapeutics
• 6.7. Genentech
• 6.8. GlaxoSmithKline
• 6.9. Icagen
• 6.10. MediciNova
• 6.11. Pfizer
• 6.12. Schering-Plough and Novartis
• 6.13. Topigen Pharmaceuticals
• 6.14. Wyeth

CHAPTER 7: SELECTED EXAMPLES OF EMERGING THERAPIES FOR TREATMENT OF ALLERGIES

• 7.1. Introduction
• 7.2. ALK-Abello and Schering-Plough
• 7.3. Allergy Therapeutics
• 7.4. Ception Therapeutics
• 7.5. Cytos Biotechnology
• 7.6. Greer Laboratories
• 7.7. Stallergenes

CHAPTER 8: IMMUNOTHERAPIES IN DEVELOPMENT FOR PREVENTING REJECTION OF ORGAN TRANSPLANTS

• 8.1. Introduction
• 8.2. APT Pharmaceuticals
• 8.3. Astellas Pharma
• 8.4. Bristol-Myers Squibb
• 8.5. Isotechnika
• 8.6. Novartis
• 8.7. Pfizer

CHAPTER 9: BUSINESS CONSIDERATIONS - THERAPIES THAT SUPPRESS OR BALANCE THE IMMUNE SYSTEM

• 9.1. Current Market and Market Potential
• 9.2. Competition
• 9.3. Strong Interest on the Part of Major Pharmaceutical Companies
• 9.4. Agreements and Mergers/Acquisitions
• 9.5. Other Major Challenges and Hurdles Being Faced by Companies
• Competition
• Potential Need for Personalized Medicine in at Least Certain Situations
• Targeted Patient Populations

CHAPTER 10: THOUGHT LEADER INTERVIEWS

• 10.1. David W. Pritchard, President and Chief Executive Officer, KaloBios
• 10.2. Randall C. Schatzman, PhD, President and Chief Executive Officer, Alder
• Biopharmaceuticals
• 10.3. Louis Vaickus, MD, Chief Medical
• Officer, Tolerx
• 10.4. Eric H. Zanelli, PhD, Vice President, Research, Peptimmune

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES

Tables

• Selected Drugs Used for Treatment of Autoimmune Diseases Included in Report
• Selected Drugs Used For Treatment of Asthma
• Selected Drugs Used For Treatment of Allergies
• Selected Drugs Used For Prevention of Rejection Following Transplants
• Selected Molecular Targets/Mechanisms of Actions For Emerging Autoimmune Disease, Asthma, and Allergy Therapies and For Prevention of Organ Transplant Rejection, With Information on Companies and Emerging Therapies Focused on Those Targets
• Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Treatment of Rheumatoid Arthritis
• Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Type 1 Diabetes
• Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Inflammatory Bowel Disease (Crohn' s Disease and Ulcerative Colitis)
• Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Multiple Sclerosis
• Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Psoriasis
• Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Psoriatic Arthritis
• Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Lupus (Systemic Lupus Ery-thematosus; Lupus Nephritis)
• Early Stage Therapies and Programs To Suppress or Balance the Immune System and/or Restore Balance - For Autoimmune Diseases (Specific Disease Indication(s) Not Specified)
• Selected Examples of Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - Disease Indi-cations Not Yet Specified
• Selected Companies Developing Therapies For Asthma
• Selected Companies Developing Therapies That Suppress or Balance the Immune System and/or Restore Balance - For Treatment of Allergies
• Selected Companies Developing Therapies for Prevention of Organ Transplant Rejection
• 2008 Sales of Selected Drugs for Treatment of Autoimmune Diseases and Asthma
• Selected Major Pharmaceutical/Biopharmaceutical Companies:
• Developing Therapies For Autoimmune Diseases, Asthma, Allergies, and/or Prevention of Organ Transplant Rejection

Related Reports